194 related articles for article (PubMed ID: 38064201)
1. An Immunomodulatory Zinc-Alum/Ovalbumin Nanovaccine Boosts Cancer Metalloimmunotherapy Through Erythrocyte-Assisted Cascade Immune Activation.
Zhao J; Zhang L; Li P; Liu S; Yu S; Chen Z; Zhu M; Xie S; Ling D; Li F
Adv Sci (Weinh); 2024 Feb; 11(6):e2307389. PubMed ID: 38064201
[TBL] [Abstract][Full Text] [Related]
2. Rough Nanovaccines Boost Antitumor Immunity Through the Enhancement of Vaccination Cascade and Immunogenic Cell Death Induction.
Zhao X; Zhang J; Chen B; Ding X; Zhao N; Xu FJ
Small Methods; 2023 May; 7(5):e2201595. PubMed ID: 36869418
[TBL] [Abstract][Full Text] [Related]
3. A Cancer Nanovaccine Based on an FeAl-Layered Double Hydroxide Framework for Reactive Oxygen Species-Augmented Metalloimmunotherapy.
Chang M; Wang M; Liu B; Zhong W; Jana D; Wang Y; Dong S; Antony A; Li C; Liu Y; Zhao Z; Lin J; Jiang W; Zhao Y
ACS Nano; 2024 Mar; 18(11):8143-8156. PubMed ID: 38436248
[TBL] [Abstract][Full Text] [Related]
4. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
[TBL] [Abstract][Full Text] [Related]
5. Ferroptosis and Necroptosis Produced Autologous Tumor Cell Lysates Co-Delivering with Combined Immnoadjuvants as Personalized
Shi W; Feng W; Li S; Cui Y; Liu S; Jiang H; Liu Y; Zhang H
ACS Nano; 2023 Aug; 17(15):14475-14493. PubMed ID: 37466500
[TBL] [Abstract][Full Text] [Related]
6. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
[TBL] [Abstract][Full Text] [Related]
7. Fe(III)-Shikonin supramolecular nanomedicines as immunogenic cell death stimulants and multifunctional immunoadjuvants for tumor vaccination.
Feng W; Shi W; Cui Y; Xu J; Liu S; Gao H; Zhu S; Liu Y; Zhang H
Theranostics; 2023; 13(15):5266-5289. PubMed ID: 37908730
[TBL] [Abstract][Full Text] [Related]
8. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.
Zhang Y; Li Q; Ding M; Xiu W; Shan J; Yuwen L; Yang D; Song X; Yang G; Su X; Mou Y; Teng Z; Dong H
Adv Healthc Mater; 2023 Jul; 12(17):e2203028. PubMed ID: 36807733
[TBL] [Abstract][Full Text] [Related]
9. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger.
Hu Y; Lin L; Chen J; Maruyama A; Tian H; Chen X
Biomaterials; 2020 Sep; 252():120114. PubMed ID: 32422491
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
[TBL] [Abstract][Full Text] [Related]
11. A natural IgM hitchhiking strategy for delivery of cancer nanovaccines to splenic marginal zone B cells.
Wang H; Wu X; Sun Y; Liu A; He Y; Xu Z; Lu Y; Zhan C
J Control Release; 2024 Apr; 368():208-218. PubMed ID: 38395156
[TBL] [Abstract][Full Text] [Related]
12. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy.
Li R; Hao Y; Pan W; Wang W; Min Y
Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924
[TBL] [Abstract][Full Text] [Related]
13. Unprecedented Chiral Nanovaccines for Significantly Enhanced Cancer Immunotherapy.
Liu H; Xie Z; Zheng M
ACS Appl Mater Interfaces; 2022 Sep; 14(35):39858-39865. PubMed ID: 36007113
[TBL] [Abstract][Full Text] [Related]
14. Nanovaccines with cell-derived components for cancer immunotherapy.
Meng Z; Zhang Y; Zhou X; Ji J; Liu Z
Adv Drug Deliv Rev; 2022 Mar; 182():114107. PubMed ID: 34995678
[TBL] [Abstract][Full Text] [Related]
15. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
[TBL] [Abstract][Full Text] [Related]
16. Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination.
Lv X; Huang J; Min J; Wang H; Xu Y; Zhang Z; Zhou X; Wang J; Liu Z; Zhao H
J Control Release; 2023 May; 357():109-119. PubMed ID: 36738971
[TBL] [Abstract][Full Text] [Related]
17. Hybrid mRNA Nano Vaccine Potentiates Antigenic Peptide Presentation and Dendritic Cell Maturation for Effective Cancer Vaccine Therapy and Enhances Response to Immune Checkpoint Blockade.
Shi L; Yang J; Nie Y; Huang Y; Gu H
Adv Healthc Mater; 2023 Dec; 12(32):e2301261. PubMed ID: 37822133
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances of Emerging Spleen-Targeting Nanovaccines for Immunotherapy.
He X; Wang J; Tang Y; Chiang ST; Han T; Chen Q; Qian C; Shen X; Li R; Ai X
Adv Healthc Mater; 2023 Sep; 12(23):e2300351. PubMed ID: 37289567
[TBL] [Abstract][Full Text] [Related]
19. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
[TBL] [Abstract][Full Text] [Related]
20.
Yu L; Yu M; Chen W; Sun S; Huang W; Wang T; Peng Z; Luo Z; Fang Y; Li Y; Deng Y; Wu M; Tao W
J Am Chem Soc; 2023 Mar; ():. PubMed ID: 36930579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
